Sarah E. Halford

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Improving preclinical and clinical oncology research through patient integration.

Improving preclinical and clinical oncology research through patient integration.

Journal: Current medical research and opinion

Published: January 28, 2026

Individual patient data meta-analysis and systematic review evaluating camostat mesilate to treat COVID-19.

Individual patient data meta-analysis and systematic review evaluating camostat mesilate to treat COVID-19.

Journal: Journal of clinical and translational science

Published: December 09, 2025

Procedures of data merging in precision cancer medicine: the PRIME-ROSE project.

Procedures of data merging in precision cancer medicine: the PRIME-ROSE project.

Journal: Acta oncologica (Stockholm, Sweden)

Published: October 17, 2025

Investigations of the novel checkpoint kinase 1 inhibitor SRA737 in non-small cell lung cancer and colorectal cancer cells of differing tumour protein 53 gene status.

Investigations of the novel checkpoint kinase 1 inhibitor SRA737 in non-small cell lung cancer and colorectal cancer cells of differing tumour protein 53 gene status.

Journal: Exploration of targeted anti-tumor therapy

Published: June 10, 2023

Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective.

Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective.

Journal: Frontiers in oncology

Published: January 13, 2023

A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer.

A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 20, 2022

Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.

Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.

Journal: Trials

Published: April 22, 2022

SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.

SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.

Journal: Trials

Published: January 22, 2021

Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.

Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.

Journal: Neuro-oncology

Published: April 30, 2020

Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.

Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.

Journal: British journal of cancer

Published: March 24, 2020

A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.

A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.

Journal: British journal of cancer

Published: June 10, 2019

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.

Journal: British journal of cancer

Published: July 31, 2017

Showing 1-12 of 21

Last Updated: 09/26/2026